Connect with us

Stocks

How does Mattel Inc. (NASDAQ: MAT) stack up right now

Published

on

It’s time to take an in-depth technical look at Mattel Inc. (NASDAQ:MAT) . Our goal here today is to examine how the stock is behaving so we can use that examination as a lens through which to evaluate the stock as a possible investment opportunity.

Technical analysis is predicated on the idea that all important information is already interpolated by buyers and sellers of a security, so the only thing left to really interpret and predict the action is that behavior itself. For market timers, one of the most important tools we have at hand is the key indicators that show whether the stock is stretched in one direction or the other too much, too far, or too fast. In other words, is the stock overbought, oversold, or somewhere in the middle?

For that, we first turn to the RSI measure. The 14-day RSI is the standard flag-bearer for this type of analysis. Right now, for Mattel Inc., the measure stands at 50.58%. That shows where the stock is as far as the degree to which it is becoming overbought or oversold relative to its price history.

If we look at other overbought/oversold oscillators, we can get even more perspective. The stochastic measure is a good example. Right now, the stock over the past month of action shows a score of 53.49% on the 20-day fast stochastic.

In an even broader sense, NASDAQ: MAT has recently been showing trading action that suggests an overall bearish posture on the chart according to trend-related measures such as a major moving average. In this case, we are looking at the relative positions of the 50-day and 200-day simple moving averages. The implication, of course, is that money is generally treating this stock in a negative manner in terms of capital flows.

Next, we want to look at participation levels. Our conviction on a stock in terms of its technicals is almost entirely subject in the end to the type of volume of trade we see going on in the stock. Patterns of action gain meaning strictly through volume levels. In other words, you need plenty of people playing the game for the score to matter. At this point, relative volume measures have been strong, indicating interest among traders, investors, and money managers for the stock over the past month. As it stands at present, the stock might find important action around key levels on the chart, which is something else we like to take a close look at.

One of the best ways to define key levels is through derivations built off of the Fibonacci series. This is widely used by professional firms in the market. The Fibonacci series is a set of numbers derived from adding the prior number to the next one: 0,1,1,2,3,5,8,13,21,34, etc. You will note that each number is the sum of the prior two numbers. The series has been found to exemplify the mathematics underlying many growth systems. The ratio of one number to the next in the series approaches 61.8% (or 38.2%, depending on which direction you move) as a limit. In markets, the key levels are often played at retracements defined by this ratio and its associated connections. In this case, the critical 38.2% level drawn off the 52-week low of $12.71 sits at $20.26. NASDAQ: MAT also has additional resistance above at the stocks 200-day simple moving average, which sits at $ 21.34.

So far, we have looked at oscillators, moving average trends, and participation levels. However, sometimes, there is information carried in simply the degree of movement in a stock. For example, over the past trading month, NASDAQ: MAT has made a move of +0.20. By comparison, over the trailing 100 days, the stock is underperforming the S&P 500 by 35.86, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange.

Obviously, that tells us a ton about this name. To even drill down deeper into the movement, we can see that the stocks recent action has come on a historical volatility score of 52.98%. That number is derived from the standard deviation of returns of some hypothetical trader buying the stock at a given average price during the specified period. If we want to look at range of action in a simplistic sense, the best way is to use the average true range over the most common reference time period, so we are staying on the same page with the market. In this case, the 20-day ATR as a percentage of its 20-day moving average comes in at 3.61%.

We plan to update our take on this stock as its pattern of behavior progresses from here.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

I graduated from UCSD with a degree in Journalism. With more than 5 years of experience in freelance journalism, my forte is covering stock fundamentals.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stocks

CA, Inc. (CA) Could Be In For A Major Breakout

Published

on

Stock of CA, Inc. (CA) opened at $32.26 and last traded at $32.12 x 800. More than 693,693 shares exchanged hands compared to an average daily volume of 1,677,896 shares. At the current pps, the market capitalization stands at 13.41B.

TriNet Group, Inc. (NYSE: TNET), a leading provider of comprehensive HR solutions, today announced that Richard Beckert has joined TriNet as senior vice president of finance. Beckert will be appointed as chief financial officer immediately following…

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. CA, Inc. (CA) currently has a Beta value of 1.04 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at CA, Inc current P/E ratio. CA, Inc. (CA) currently has a PE ratio of 17.80. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at CA, Inc beta and P/E ratio, the EPS cannot be ignored. CA, Inc EPS for the trailing twelve months was 1.80. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. CA, Inc is estimated to release its next earnings report on 3 / 2018 (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

CA, Inc. (CA) has received an average target price from analysts of $32.95 amounting to a recommendation rating of Hold. That comes from 17 different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of 13.19. To give a sense of trend, the same data point on the estimate for next year is currently sitting at 12.68 times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of 14.00. That shift to 14.00 heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

Stocks

Why BioMarin Pharmaceutical Inc. (BMRN) could blow up your portfolio

Published

on

Stock of BioMarin Pharmaceutical Inc. (BMRN) opened at $81.82 and last traded at $81.32 x 200. More than 539,968 shares exchanged hands compared to an average daily volume of 1,351,136 shares. At the current pps, the market capitalization stands at 14.27B.

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. BioMarin Pharmaceutical Inc. (BMRN) currently has a Beta value of 1.42 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at BioMarin Pharmaceutical Inc current P/E ratio. BioMarin Pharmaceutical Inc. (BMRN) currently has a PE ratio of N/A. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at BioMarin Pharmaceutical Inc beta and P/E ratio, the EPS cannot be ignored. BioMarin Pharmaceutical Inc EPS for the trailing twelve months was -1.07. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. BioMarin Pharmaceutical Inc is estimated to release its next earnings report on N/A (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

BioMarin Pharmaceutical Inc. (BMRN) has received an average target price from analysts of ${{marketwatch_AverageTargetPrice}} amounting to a recommendation rating of {{marketwatch_AverageRecommendation}}. That comes from {{marketwatch_NumberofRatings}} different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of {{marketwatch_MedianPEonCYEstimate}}. To give a sense of trend, the same data point on the estimate for next year is currently sitting at {{marketwatch_MedianPEonNextFYEstimate}} times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of {{marketwatch_NoofEstimates_this_quarter}}. That shift to {{marketwatch_NoofEstimates_next_quarter}} heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

Stocks

Biogen Inc. (BIIB) finding value in an unloved sector

Published

on

Stock of Biogen Inc. (BIIB) opened at $309.69 and last traded at $312.51 x 200. More than 463,536 shares exchanged hands compared to an average daily volume of 1,353,516 shares. At the current pps, the market capitalization stands at 65.71B.

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. Biogen Inc. (BIIB) currently has a Beta value of 1.37 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at Biogen Inc current P/E ratio. Biogen Inc. (BIIB) currently has a PE ratio of 20.39. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at Biogen Inc beta and P/E ratio, the EPS cannot be ignored. Biogen Inc EPS for the trailing twelve months was 15.24. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. Biogen Inc is estimated to release its next earnings report on 12 / 2017 (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

Biogen Inc. (BIIB) has received an average target price from analysts of $352.87 amounting to a recommendation rating of Overweight. That comes from 35 different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of 14.07. To give a sense of trend, the same data point on the estimate for next year is currently sitting at 13.18 times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of 29.00. That shift to 13.00 heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

 


Lithium Stocks

 

Trending